Table 3.
Recommended screening tool, by anal cancer risk sub-group.
| Screening Tool | People Living with HIV |
HIV Negative |
HIV Not specified |
EGW |
HSIL |
Cancer |
P-Value | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MSM (n = 139) n (%) |
Women (n = 138) n (%) |
MSW (n = 128) n (%) |
MSM (n = 122) n (%) |
Non-HIV immuno- suppression (n = 131) n (%) |
TGW (n = 121) n (%) |
Genital n = 106 n (%) |
Cervico-vaginal (n = 133) n (%) |
Vulvar (n = 137) n (%) |
Cervico-vaginal (n = 137) n (%) |
Vulvar (n = 139) n (%) |
||
| Anal Cytology | 125 (90) | 123 (89) | 115 (90) | 107 (88) | 101 (77) | 102 (84) | 86 (81) | 110 (83) | 114 (83) | 114 (83) | 119 (83) | 0.06 |
| DARE | 116 (83) | 110 (80) | 105 (82) | 102 (84) | 99 (76) | 98 (81) | 91 (86) | 100 (75) | 102 (74) | 104 (76) | 105 (76) | 0.38 |
| HrHPV | 65 (47) | 67 (49) | 64 (50) | 62 (51) | 52 (40) | 54 (45) | 51 (48) | 66 (50) | 66 (48) | 67 (49) | 68 (49) | 0.87 |
| HRAa | 81 (58) | 69 (50) | 61 (40) | 44 (36) | 43 (33) | 43 (36) | 45 (42) | 58 (44) | 64 (47) | 64 (47) | 72 (52) | <0.01 |
| Cytology plus DARE | 106 (76) | 101 (73) | 93 (73) | 89 (73) | 82 (63) | 86 (71) | 71 (67) | 87 (65) | 91 (66) | 93 (68) | 96 (69) | 0.40 |
a
Statistically significant.